The Synergy IOL employs a hybrid technology that provides both multifocal and EDOF diffractive optics. Theoretically and clinically this range should be more complete than traditional trifocal or EDOF-only technologies. Benchmark testing of this lens suggests that it can achieve a high level of visual acuity over a range of vision.3 To achieve a high quality of visual functioning over a range of vision, the optics of the Synergy IOL, similar to its predecessor EDOF-only Symfony IOL, correct for different types of aberration, including chromatic and spherical, providing an extremely high peak in its defocus curve.6 The clinical trials used for FDA approval for this lens reported results of monocular and binocular acuity at 40 cm (primary endpoint), as well as 33 and 66 cm, in addition to distance (secondary endpoints). Other studies have evaluated two and up to three near focal lengths. This study included an intermediate target of 50 cm instead of 40 cm, which the study author’s clinical experience has been more representative of required distance for intermediate vision tasks, especially in the use of a laptop computer or desktop monitor in the daily lives of many patients.
This study demonstrated that patients achieved an excellent level of DCIVA at 50 cm, along with excellent near, distance, and traditional 66 cm intermediate vision as shown in past studies. The FDA clinical trial results measured near and intermediate visual acuity up to the 20/40 level—beyond that, eyes were grouped together. The author’s experience is consistent with 20/40 (0.30 logMAR), or J3 on a near card, as a suitable target size of print to satisfy most daily intermediate tasks including computer screen work.
This study is limited by its retrospective nature and the lack of a control group. All surgeries, however, were performed by one surgeon and techniques for measuring visual outcomes in the clinic were standardized between the surgeon and the chief technician performing visual and refractive assessments. As such, it is felt that the retrospective design does not significantly impact the nature of visual outcomes reported here. One limitation of this study is that the use of a near acuity card in ideal lighting conditions may overestimate outcomes in patients who are subject to extended periods of reading or for reading in non-ideal conditions. This method of testing of near vision, however, is consistent with that employed by most clinicians when measuring patient outcomes in a normal clinical setting. Furthermore, the Synergy IOL has demonstrated that, with similar visual acuity outcomes as seen in this study, good real world reading outcomes are experienced.16
This study was not designed to capture side effects such as positive dysphotopsias or overall satisfaction rates of patients undergoing phacoemulsification with the Synergy IOL since detailed questionnaires are not routinely administered in our setting. Nevertheless, a review of all clinic notes revealed that, even though some patients did report glare or haloes on their final postop visit, no patient was dissatisfied with their IOL or required additional followup visits to manage persistent dysphotopsias. The Synergy IOL is designed with a proprietary violet light-filtering chromophore that reduces transmittance of violet wavelengths of light, which may contribute to an improved rate of dysphotopsias compared to similar IOLs without this reduction in transmission of shorter wavelength violet light.17